{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:37:57Z","timestamp":1784216277934,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI22CIII\/00004"],"award-info":[{"award-number":["FI22CIII\/00004"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23CIII\/00024"],"award-info":[{"award-number":["PI23CIII\/00024"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0017\/0005"],"award-info":[{"award-number":["RD21\/0017\/0005"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17CIII\/00013"],"award-info":[{"award-number":["PI17CIII\/00013"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20CIII-00040"],"award-info":[{"award-number":["PI20CIII-00040"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["RED2022-134221-T"],"award-info":[{"award-number":["RED2022-134221-T"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","award":["NEXT_GEN_CART_MADCM"],"award-info":[{"award-number":["NEXT_GEN_CART_MADCM"]}],"id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","award":["2018-T2\/BMD-10337"],"award-info":[{"award-number":["2018-T2\/BMD-10337"]}],"id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","award":["P2022\/BMD7225"],"award-info":[{"award-number":["P2022\/BMD7225"]}],"id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008545","name":"Asociaci\u00f3n Pablo Ugarte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030719","name":"National Institute of Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017642","name":"Spanish National Plan for Scientific and Technical Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omton.2024.200863","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T18:54:28Z","timestamp":1724439268000},"page":"200863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T\u00a0cell therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Alvaro","family":"Morales-Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Rodriguez-Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garcia-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garcia-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200863_bib1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00262-017-2025-8","article-title":"Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer","volume":"66","author":"Hamid","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200863_bib2","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200863_bib3","first-page":"309","article-title":"Long-term results in combined-modality treatment of small cell carcinoma of the lung","volume":"5","author":"Einhorn","year":"1978","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.omton.2024.200863_bib4","first-page":"999","volume":"63","year":"1985","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.omton.2024.200863_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/cts.12391","article-title":"Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities","volume":"9","author":"Morrissey","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.omton.2024.200863_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omton.2024.200863_bib7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Combination therapy with CAR T\u00a0cells and oncolytic viruses: a new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2024.200863_bib8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/sj.mt.6300239","article-title":"Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway","volume":"15","author":"Cascallo","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200863_bib9","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.1158\/0008-5472.CAN-06-4675","article-title":"ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in\u00a0vivo","volume":"67","author":"Alonso","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200863_bib10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/mt.2014.7","article-title":"A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology","volume":"22","author":"Laborda","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200863_bib11","doi-asserted-by":"crossref","first-page":"10543","DOI":"10.1200\/JCO.2018.36.15_suppl.10543","article-title":"First-in-child trial of celyvir (autologous mesenchymal stem cells carrying the oncolytic virus ICOVIR-5) in patients with relapsed and refractory pediatric solid tumors","volume":"36","author":"Ramirez","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200863_bib12","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1158\/0008-5472.CAN-17-3754","article-title":"Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy","volume":"78","author":"Cejalvo","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200863_bib13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200863_bib14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41417-020-0184-9","article-title":"AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses","volume":"28","author":"Rodr\u00edguez-Milla","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2024.200863_bib15","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1128\/JVI.80.3.1487-1496.2006","article-title":"Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors","volume":"80","author":"Keriel","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1556\/EuJMI.1.2011.4.3","article-title":"Adenovirus-triggered innate signalling pathways","volume":"1","author":"Fejer","year":"2011","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"10.1016\/j.omton.2024.200863_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-virology-092818-015550","article-title":"Adenovirus Entry: From Infection to Immunity","volume":"6","author":"Greber","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omton.2024.200863_bib18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00018-002-8453-3","article-title":"Signalling in viral entry","volume":"59","author":"Greber","year":"2002","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omton.2024.200863_bib19","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1128\/JVI.74.22.10639-10649.2000","article-title":"Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway","volume":"74","author":"Soudais","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0168-1702(99)00087-8","article-title":"Adenovirus type 41 lacks an RGD alpha(v)-integrin binding motif on the penton base and undergoes delayed uptake in A549 cells","volume":"64","author":"Albinsson","year":"1999","journal-title":"Virus Res."},{"key":"10.1016\/j.omton.2024.200863_bib21","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/JVI.79.2.1053-1061.2005","article-title":"Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib22","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1073\/pnas.0308368101","article-title":"Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway","volume":"101","author":"Philpott","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200863_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.immuni.2009.04.015","article-title":"Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in\u00a0vivo","volume":"31","author":"Di Paolo","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2024.200863_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.virol.2014.08.027","article-title":"Inefficient export of viral late mRNA contributes to fastidiousness of human adenovirus type 41 (HAdV-41) in 293 cells","volume":"468\u2013470","author":"Zou","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.omton.2024.200863_bib25","doi-asserted-by":"crossref","first-page":"45415","DOI":"10.18632\/oncotarget.17557","article-title":"Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model","volume":"8","author":"Rincon","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2024.200863_bib26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00262-018-2220-2","article-title":"Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice","volume":"67","author":"Morales-Molina","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200863_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/2767-9764.CRC-22-0365","article-title":"Toll-like Receptor Signaling-deficient Cells Enhance Antitumor Activity of Cell-based Immunotherapy by Increasing Tumor Homing","volume":"3","author":"Morales-Molina","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.omton.2024.200863_bib28","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00262-023-03437-z","article-title":"Switchable CAR T\u00a0cell strategy against osteosarcoma","volume":"72","author":"Hidalgo","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200863_bib29","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200863_bib30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2024.200863_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"the World First Oncolytic Virus Medicine and its Update in China","volume":"18","author":"Oncorine","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.omton.2024.200863_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200863_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/v15020358","article-title":"A Renaissance for Oncolytic Adenoviruses?","volume":"15","author":"Blanchette","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2024.200863_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052517","article-title":"Oncolytic Adenoviruses for Cancer Therapy","volume":"22","author":"Tripodi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2024.200863_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.molcel.2004.11.041","article-title":"The structure of the human adenovirus 2 penton","volume":"17","author":"Zubieta","year":"2005","journal-title":"Mol. Cell."},{"key":"10.1016\/j.omton.2024.200863_bib36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/104303403321618146","article-title":"The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors","volume":"14","author":"Liu","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2024.200863_bib37","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","article-title":"An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism","volume":"72","author":"Dmitriev","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/hum.2014.001","article-title":"Innate immunity to adenovirus","volume":"25","author":"Hendrickx","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2024.200863_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/43466","article-title":"NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase","volume":"401","author":"Ozes","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.omton.2024.200863_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/43474","article-title":"NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling","volume":"401","author":"Romashkova","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.omton.2024.200863_bib41","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.gt.3302036","article-title":"Molecular basis of the inflammatory response to adenovirus vectors","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2024.200863_bib42","doi-asserted-by":"crossref","first-page":"14507","DOI":"10.1128\/JVI.79.23.14507-14515.2005","article-title":"Akt\/protein kinase B activation by adenovirus vectors contributes to NFkappaB-dependent CXCL10 expression","volume":"79","author":"Liu","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib43","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib44","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/JVI.02368-08","article-title":"Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1","volume":"83","author":"Raman","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib45","doi-asserted-by":"crossref","first-page":"10354","DOI":"10.1128\/JVI.00936-14","article-title":"Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity","volume":"88","author":"Teigler","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib46","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"Teigler","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omton.2024.200863_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/v14050888","article-title":"Cytokine Responses to Adenovirus and Adenovirus Vectors","volume":"14","author":"Atasheva","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2024.200863_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000959","article-title":"Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization","volume":"6","author":"Smith","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omton.2024.200863_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.chom.2007.12.001","article-title":"Mechanism of adenovirus neutralization by Human alpha-defensins","volume":"3","author":"Smith","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.omton.2024.200863_bib50","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/1873-3468.13696","article-title":"Innate immunity to adenovirus: lessons from mice","volume":"593","author":"Atasheva","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omton.2024.200863_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2024.200863_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T\u00a0cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2024.200863_bib53","first-page":"2064","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omton.2024.200863_bib54","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.4049\/jimmunol.1002771","article-title":"NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus","volume":"185","author":"Zhu","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omton.2024.200863_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T\u00a0cells within the tumor microenvironment following CAR T\u00a0cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2024.200863_bib56","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8(+) T\u00a0cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.omton.2024.200863_bib57","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.omto.2023.04.008","article-title":"Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy","volume":"29","author":"Mamola","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2024.200863_bib58","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.gt.3301701","article-title":"CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice","volume":"9","author":"Mizuguchi","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2024.200863_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jim.2012.06.005","article-title":"Area under the curve as a tool to measure kinetics of tumor growth in experimental animals","volume":"382","author":"Duan","year":"2012","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.omton.2024.200863_bib60","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells","volume":"23","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992400105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992400105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:46Z","timestamp":1778938666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032992400105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S295032992400105X"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200863","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T\u00a0cell therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200863"}}